利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

22 条记录 (耗时 0.044 秒)

    Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label
    15.
    发明授权
    Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label 有权
    结合肿瘤抗原的第一非标记单克隆抗体和用NIR荧光标记标记的非交叉反应性第二单克隆抗体的组成

    公开(公告)号：US08529901B2

    公开(公告)日：2013-09-10

    申请号：US12599713

    申请日：2008-06-04

    申请人： Max Hasmann ,  Helmut Lenz ,  Werner Scheuer

    发明人： Max Hasmann ,  Helmut Lenz ,  Werner Scheuer

    IPC分类号： A61K39/395

    CPC分类号： A61K49/0058 ,  A61K39/39558 ,  A61K49/0032

    摘要： This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patient with such composition.

    摘要翻译： 本发明涉及结合肿瘤抗原的非标记单克隆抗体的组合物和用NIR荧光标记物标记的第二单克隆抗体，其结合相同的肿瘤抗原，其中第一抗体和第二抗体不显示交叉反应性。 该组合物可用于治疗与这种肿瘤抗原的过表达相关的实体瘤患者。 本发明还涉及所述第一和第二抗体的共同给药，以获得在用所述组合物治疗所述患者期间获得这种肿瘤的NIR荧光图像或患有此类肿瘤的患者的方法。

    TUMOR THERAPY WITH A COMBINATION OF ANTI-HER2 ANTIBODIES
    17.
    发明申请
    TUMOR THERAPY WITH A COMBINATION OF ANTI-HER2 ANTIBODIES 审中-公开
    肿瘤治疗与抗HER2抗体的组合

    公开(公告)号：US20080102069A1

    公开(公告)日：2008-05-01

    申请号：US11854584

    申请日：2007-09-13

    申请人： Thomas Friess ,  Max Hasmann ,  Werner Scheuer

    发明人： Thomas Friess ,  Max Hasmann ,  Werner Scheuer

    IPC分类号： A61K39/395 ,  A61P35/00

    CPC分类号： C07K16/32 ,  A61K2039/507 ,  C07K2317/24

    摘要： The present invention provides a method for treating HER2 positive cancer or metastasis of HER2 positive cancer in a patient, who does not respond to a monotherapy with trastuzumab or a monotherapy with pertuzumab or to successive monotherapies with trastuzumab and pertuzumab, comprising co-administering to said patient a therapeutically-effective amount of trastuzumab and pertuzumab simultaneously or sequentially. The invention also provides A kit which comprises trastuzumab and pertuzumab and a package insert instructing the user to co-administer trastuzumab and pertuzumab to a patient suffering from HER2 positive cancer who does not respond to a monotherapy with trastuzumab or a monotherapy with pertuzumab.

    摘要翻译： 本发明提供了一种用于治疗HER2阳性癌症的HER2阳性癌症或转移的方法，所述方法不对曲妥珠单抗单药治疗或使用妥他珠单抗或与曲妥单抗和依托单抗连续单药治疗无反应，包括共同施用 同时或顺序地向患者提供治疗有效量的曲妥单抗和依妥珠单抗。 本发明还提供了一种试剂盒，其包含曲妥珠单抗和依妥珠单抗和包装说明书，其指示使用者将曲妥珠单抗和依托单抗联合给患有HER2阳性癌症的患者，其对曲妥珠单抗的单一疗法或使用妥珠单抗的单一疗法无反应。

    COMPOSITION OF A FIRST NON-LABELED MONOCLONAL ANTIBODY BINDING TO A TUMOR ANTIGEN AND A NON-CROSS REACTIVE SECOND MONOCLONAL ANTIBODY LABELED WITH A NIR FLUORESCENCE LABEL
    20.
    发明申请
    COMPOSITION OF A FIRST NON-LABELED MONOCLONAL ANTIBODY BINDING TO A TUMOR ANTIGEN AND A NON-CROSS REACTIVE SECOND MONOCLONAL ANTIBODY LABELED WITH A NIR FLUORESCENCE LABEL 有权
    第一个非标记的单克隆抗体与肿瘤抗原结合的组合物和标记有近红色荧光标记的非交叉反应性第二单克隆抗体

    公开(公告)号：US20110027190A1

    公开(公告)日：2011-02-03

    申请号：US12599713

    申请日：2008-06-04

    申请人： Max Hasmann ,  Helmut Lenz ,  Werner Scheuer

    发明人： Max Hasmann ,  Helmut Lenz ,  Werner Scheuer

    IPC分类号： A61K49/00 ,  A61P35/00 ,  A61K39/395

    CPC分类号： A61K49/0058 ,  A61K39/39558 ,  A61K49/0032

    摘要： This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patient with such composition.

    摘要翻译： 本发明涉及结合肿瘤抗原的非标记单克隆抗体的组合物和用NIR荧光标记标记的第二单克隆抗体，其结合相同的肿瘤抗原，其中第一抗体和第二抗体不表现出交叉反应性。 该组合物可用于治疗与这种肿瘤抗原的过表达相关的实体瘤患者。 本发明还涉及所述第一和第二抗体的共同给药，以获得在用所述组合物治疗所述患者期间获得这种肿瘤的NIR荧光图像或患有此类肿瘤的患者的方法。